Dr. Andre Boulet reports

DEVONIAN HEALTH GROUP RECEIVES A NOTICE OF ALLOWANCE FOR ISSUANCE OF A U.S. PATENT ON A METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE.

The United States Patent and Trademark Office (USPTO) has issued a notice of allowance for Devonian Health Group Inc.'s patent application No. 16/998.004, entitled "Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease." This U.S. patent application is an addition to Devonian's existing patent portfolio relating to thylakoids developed by the company such as PUR0110 (thykamine). The allowed U.S patent application is directed to a method for treating inflammatory bowel disease (IBD) such as ulcerative colitis and Crohn's disease in a human subject with an effective amount of active thylakoid extract.

About Devonian Health Group Inc.

Devonian Health Group is a late-stage botanical pharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis.

We seek Safe Harbor.